Sidoti Research Analysts Cut Earnings Estimates for PRE

Prenetics Global Limited (NASDAQ:PRE) – Analysts at Sidoti reduced their Q3 2027 EPS estimates for Prenetics Global in a research report issued to clients and investors on Friday, February 20th. Sidoti analyst A. Hantman now anticipates that the company will post earnings of $0.71 per share for the quarter, down from their previous forecast of $0.76. The consensus estimate for Prenetics Global’s current full-year earnings is ($3.30) per share. Sidoti also issued estimates for Prenetics Global’s Q4 2027 earnings at $1.19 EPS and FY2027 earnings at $1.65 EPS.

A number of other brokerages have also weighed in on PRE. Wall Street Zen lowered Prenetics Global from a “buy” rating to a “hold” rating in a research note on Monday, February 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a report on Thursday, January 22nd. Cantor Fitzgerald increased their price objective on Prenetics Global from $26.00 to $32.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Finally, Roth Mkm began coverage on shares of Prenetics Global in a research report on Wednesday, February 11th. They issued a “buy” rating and a $36.00 target price for the company. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Prenetics Global presently has a consensus rating of “Hold” and a consensus target price of $34.00.

Prenetics Global Stock Down 11.7%

Shares of PRE stock opened at $17.05 on Monday. Prenetics Global has a 12-month low of $3.09 and a 12-month high of $22.86. The company has a market capitalization of $286.95 million, a PE ratio of -4.24 and a beta of 0.35. The firm has a 50 day moving average price of $17.80 and a two-hundred day moving average price of $14.07.

Prenetics Global (NASDAQ:PRE) last posted its earnings results on Wednesday, February 18th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.22. Prenetics Global had a negative net margin of 61.33% and a negative return on equity of 19.07%. The company had revenue of $36.60 million during the quarter, compared to analysts’ expectations of $36.15 million.

Institutional Investors Weigh In On Prenetics Global

Institutional investors and hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN bought a new position in Prenetics Global in the 4th quarter valued at about $47,000. JPMorgan Chase & Co. acquired a new stake in shares of Prenetics Global during the 3rd quarter worth approximately $65,000. Stevens Capital Partners acquired a new stake in shares of Prenetics Global during the 2nd quarter worth approximately $137,000. Manatuck Hill Partners LLC bought a new position in Prenetics Global in the fourth quarter valued at approximately $170,000. Finally, T3 Companies LLC acquired a new position in Prenetics Global during the fourth quarter valued at approximately $170,000. Institutional investors own 25.01% of the company’s stock.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.